Charity Navigator, America’s largest and most-utilized independent evaluator of charities, has awarded the Rheumatology Research Foundation its ninth consecutive 4-star rating. The prestigious 4-star rating is the highest possible rating given and is based on good governance, sound fiscal management and commitment to accountability and transparency. “The Rheumatology Research Foundation is proud to receive this…
Persistent Challenges Sometimes the challenges seem neverending. In addition to the rigors of our daily lives as rheumatology health professionals—growing administrative burdens, increasing pressures to fund research and achieve balance in family and personal lives—we face a growing number of challenges related to the rapidly escalating prices of rheumatology treatments. Even more unfortunately, these costs…
4 Patients in 4 Weeks Baltimore is a little over two hours away from Richmond, Va., by car. I know this now because I recently drove to Richmond to attend a memorial service. I drove in silence. Music made me sleepy, and I could not bear to listen to another iteration of how we are…
The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….
NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…
Several major health plans have recently enacted policies regarding coverage status for Remicade (infliximab) and its biosimilars, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda). Most of these plans are limiting coverage for the biosimilar products to very specific circumstances. Some have also begun denying claims for biosimilars and instructing patients to switch to Remicade. The plans implementing…
Prior authorization treatment delays, the preferred status conferred on some drugs by pharmacy benefit managers and exorbitant co-payments were among the issues brought before the U.S. Senate Special Committee on Aging on Wednesday, Feb. 7. William F. Harvey, MD, MSc, FACR, a practicing rheumatologist at Tufts Medical Center in Boston and volunteer on the ACR…
NEW YORK (Reuters Health)—People with gout face a modestly increased risk, of about 20%, for developing osteoporosis, compared to people without gout, researchers in Taiwan suggest. In their population-based study to examine a possible association between gout and subsequent osteoporosis, Dr. Victor C. Kok of Asia University (Taiwan), Taichung, and colleagues retrospectively analyzed data from…
The Insurance Subcommittee (ISC) of the ACR’s Committee on Rheumatologic Care (CORC) has recently received a number of reports from members regarding denials for biologics for patients not on methotrexate. To help avoid an often-lengthy appeals process, the ACR/ARHP recommends that members document a patient’s history of methotrexate intolerance or contraindication at every visit. What…
In the ever-changing healthcare delivery landscape, the ACR continues to go to work on behalf of its members to ensure public policies encourage delivery of high-quality rheumatology care and treatment. With stepped-up efforts to meet with federal administrative and Congressional representatives, and broadened coalitions of partners to strengthen advocacy for key issues important to the…